Studies involving men who have sex with men include; IPrEx, Proud Study and IPERGAY. To date, studies have shown PrEP to be safe and highly effective in preventing HIV infections.

Various PrEP study results may seem confusing and at times conflicting but the simple message is, adhering to PrEP as directed by your doctor can offer you very high levels of protection from acquiring HIV. HIV experts suggest that if used correctly, PrEP can offer up to 99% protection from HIV. The key to effective HIV protection from using PrEP is adherence.

PROUD Study

Article Proud Study

‘…findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection’

PROUD PrEP study results published

Pre-exposure prophylaxis (PrEP) stops 86% of HIV infections in PROUD study 

Presentation PROUD Study

Pragmatic Open-Label Randomised Trial of Pre exposure Prophylaxis: The PROUD Study

View webcast

By Sheena McCormack
MRC Clinical Trails Unit at University College London, London, United Kingdom.
Conference of Retroviral and Opportunistic Infections (CROI), 2015.

IPERGAY Study

Article IPERGAY STUDY

‘…certainly no evidence that anyone who had been taking Truvada had become infected’

Molina J-M et al. On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. 2015 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, abstract 23LB, 2015.

Pre-exposure prophylaxis also stops 86% of HIV infections in Ipergay study

Presentation IPERGAY

On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial
View Webcast

Jean-Michel Molina
University of Paris Diderot, Paris, France.
Conference of Retroviral and Opportunistic Infections (CROI), 2015.

San Francisco Program 

Article San Francisco Program

No HIV infections seen in San Francisco PrEP users referred via primary care
‘…not seen a single HIV infection in people using PrEP since it started in 2012’

No HIV infections seen in San Francisco PrEP users referred via primary care

Presentation San Francisco Program

Scale-Up of Pre exposure Prophylaxis in San Francisco to Impact HIV Incidence
View Webcast

Robert M. (2015) Grant Scale-Up of Pre exposure Prophylaxis in San Francisco to Impact HIV Incidence
Gladstone Institutes, San Francisco, CA, United States

Robert M. Grant
Gladstone Institute, San Francisco, CA, United States.
Conference of Retroviral and Opportunistic Infections (CROI), 2015.

IpREx Study

Article IpREx Study

‘Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week’
‘…there were no infections in participants with drug levels consistent with taking PrEP at least four times a week’

Overall PrEP effectiveness in iPrEx OLE study 50%, but 100% in those taking four or more doses a week

Results of the iPrEx open-label extension

The iPrEx study

How will people use PrEP? iPrEx users talk condoms, pills, anxiety and relief